Please assess the completion status of the following clinical trial:

Trial Title: Firmagon (Degarelix) Intermittent Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed adenocarcinoma of the prostate for which intermittent endocrine treatment therapy is indicated~* PSA level meeting both of these criteria:~* PSA level of ≥ 5 ng/mL.~* For patients with recurrence after radiotherapy or cryotherapy: Patients should have a serum PSA (two measurements) to be \>2 ng/mL higher than a previously confirmed PSA nadir.~* screening serum testosterone level above the lower limit of normal range defined as \>2.2 ng/mL.~Exclusion Criteria:~* Has had previous or is currently under hormonal management of prostate cancer (surgical castration or other hormonal manipulation)~* Has received therapy with the 5-alpha reductase inhibitors finasteride or dutasteride within 12 weeks and 25 weeks, respectively, prior to screening

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 10 month degarelix therapy (Type: ACTIVE_COMPARATOR): None
- 4 month degarelix therapy arm (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).